The two studies describe methods for identifying off-target mutations associated with cell-type-specific SNPs and detecting potential off-target cleavage sites.
The University of California, University of Vienna, and researcher Emmanuelle Charpentier, as well as their commercial partners, are linked by the agreement.
After CRISPR/Cas9 makes a double-strand break in DNA and the cell repairs it, the same set of mutations crop up again and again based on the genomic sequence.
While reimbursement and regulatory issues may make some cautious, investors are encouraged by the promise of breakthrough outcomes in a variety of applications.
Caribou will license its CRISPR technology to Genus to help it create pigs that are resistant to Porcine Reproductive and Respiratory Syndrome Virus.
The financing round includes new investors Anterra Capital, Heritage Group, Maverick Capital Ventures, and Pontifax AgTech.
The Berkeley, California-based company is aiming to turn CRISPR into a platform technology for clinical and industrial applications.
The USPTO has become involved in the CRISPR-Cas9 patent dispute.
As the interference proceeding to resolve claims in foundational CRISPR patents draws near, Caribou has given IDT worldwide rights to sell RUO reagents.
New Scientist reports that 20 percent of human and yeast proteins are uncharacterized.
University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.
In Nature this week: protein-coding variants associated with body-fat distribution, and more.
NPR reports that researchers in Italy are testing a gene drive aimed at controlling mosquito populations.